Medivir AB (Medivir AB) Change In Receivables : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Medivir AB Change In Receivables?

Medivir AB's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Medivir AB's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Medivir AB's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.40 Mil. It means Medivir AB's Accounts Receivable increased by $0.40 Mil from Dec. 2022 to Dec. 2023 .

Medivir AB's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Medivir AB's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Medivir AB's liquidation value for the three months ended in Dec. 2023 was $9.70 Mil.

Medivir AB Change In Receivables Historical Data

The historical data trend for Medivir AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Change In Receivables Chart

Medivir AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

0.53

1.03

0.53

-0.08

-0.40

Medivir AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Medivir AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Medivir AB (OTCPK:MVRBF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Medivir AB's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.432	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Medivir AB's accounts receivable are only considered to be worth 75% of book value:

Medivir AB's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	16.526	-	6.823	+	0.75 * 0	+	0.5 * 0
=	9.70

Medivir AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of Medivir AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivir AB (Medivir AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MVIR:Sweden MVR0:Germany

Address

Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22

Website

https://www.medivir.com

Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.